about
TLR4 and Insulin Resistance.Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice.NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma.NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.Gut microbiota-associated bile acid deconjugation accelerates hepatic steatosis in ob/ob mice.Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity.Serum fetuin-A levels related with microalbuminuria in diet-induced obese rats.Green tea extract provides extensive Nrf2-independent protection against lipid accumulation and NFκB pro- inflammatory responses during nonalcoholic steatohepatitis in mice fed a high-fat diet.Obesity enhances sepsis-induced liver inflammation and injury in miceFoetal programming by methyl donor deficiency produces steato-hepatitis in rats exposed to high fat diet.Effects of glutamine on oxidative stress and nuclear factor-κB expression in the livers of rats with nonalcoholic fatty liver disease.Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked?Non alcoholic steatohepatitis is associated with subclinical impairment in left ventricular function measured by speckle tracking echocardiography.Role of nuclear factor kappaB in liver health and disease.Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver diseaseThe importance of the long-chain polyunsaturated fatty acid n-6/n-3 ratio in development of non-alcoholic fatty liver associated with obesity.Identification of cytochrome CYP2E1 as critical mediator of synergistic effects of alcohol and cellular lipid accumulation in hepatocytes in vitro.Green tea extract suppresses NFκB activation and inflammatory responses in diet-induced obese rats with nonalcoholic steatohepatitis.Immunoregulation by lipids during the development of non-alcoholic steatohepatitis.Connexin 32 and luteolin play protective roles in non-alcoholic steatohepatitis development and its related hepatocarcinogenesis in rats.Mechanisms and clinical implications of hepatocyte lipoapoptosis.Oxidative stress signaling underlying liver disease and hepatoprotective mechanismsEffect of Alkaloids from Nelumbinis Plumula against Insulin Resistance of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Mice.Vanillin suppresses Kupffer cell-related colloidal carbon-induced respiratory burst activity in isolated perfused rat liver: anti-inflammatory implications.Dietary Flaxseed Oil Prevents Western-Type Diet-Induced Nonalcoholic Fatty Liver Disease in Apolipoprotein-E Knockout Mice.Mouse Models of Bariatric Surgery.N-3 long-chain PUFA supplementation prevents high fat diet induced mouse liver steatosis and inflammation in relation to PPAR-α upregulation and NF-κB DNA binding abrogation.Molecular adaptations underlying the beneficial effects of hydroxytyrosol in the pathogenic alterations induced by a high-fat diet in mouse liver: PPAR-α and Nrf2 activation, and NF-κB down-regulation.Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease.
P2860
Q34097407-25965AE0-53AC-4F13-BEF8-FAEEC2552FEFQ34779049-0FF7A240-AD88-44FE-973D-4FC651E6F486Q34980525-F1704039-8862-4F7C-9F5A-E4B5EBF6D9F1Q35808323-A7147B16-9C56-4B26-9CDF-80431D87B1FFQ35931190-0073B518-CBE0-425B-BBC9-B0BE96A5DD2FQ35998233-BCBC58EB-C97A-47A1-BF10-D9582C7277D3Q36478196-002F432F-0F3F-48CE-AB48-166BFB596A59Q36665115-D44E1F7D-439F-4DE5-A8D8-09EE2E63FA2AQ36788693-3A011134-4D3B-4C3E-B1FF-B05B58EB8B26Q37047784-38959CD7-1E28-4FE6-BF8E-77E65A2723E1Q37419162-C2337659-F20E-4056-8065-43E041533CBAQ37435670-9313DDB4-4BE9-48C1-9A9B-CE77B9D4AA19Q37470376-E028EE5C-E180-4ABE-B607-479B31C620E0Q37680608-770D4226-4EFB-4019-A71B-F6CD31E0E8ECQ37720780-DA5D0AE4-4F14-452C-A015-EC34D73CE0BFQ37844020-408EF907-04DD-49A6-8719-27B027326BBFQ37947064-59656E6C-A9C9-4713-A8D8-B9AD2E048FE8Q38310825-26C19234-E351-416A-A769-233B3755BE9EQ38329608-6ECB8061-22EC-421E-856F-6DCAD5B785F0Q38365029-91782DDC-0C57-416A-B596-C93EE1EAAE80Q38825737-607941A8-5746-496F-B399-B3644BC67E66Q39845029-458C1DDC-AC51-4A11-AF1D-34BD47BF1B30Q41129404-D5F9CC49-58BC-4B93-8FF1-C43A57E81936Q41430210-A8C4E416-6ABA-4459-AE29-B7DD71DCDB7BQ42513147-971F9315-A6C0-42AB-B209-5150673E8BD6Q42730581-7CA8D41B-6CDD-4242-A2E7-D9DB67DA6E45Q42968773-12C3807D-5529-4D34-8D1E-71B6DF534A3AQ44097830-07DA7A07-F743-4D62-8B8A-520906828D06Q51068045-DEAB9BD6-BC14-41BF-8F86-6EDD46F84504Q55223200-74143422-655D-49DD-BC9F-8866D025E52E
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Liver NF-kappaB and AP-1 DNA binding in obese patients.
@en
Liver NF-kappaB and AP-1 DNA binding in obese patients.
@nl
type
label
Liver NF-kappaB and AP-1 DNA binding in obese patients.
@en
Liver NF-kappaB and AP-1 DNA binding in obese patients.
@nl
prefLabel
Liver NF-kappaB and AP-1 DNA binding in obese patients.
@en
Liver NF-kappaB and AP-1 DNA binding in obese patients.
@nl
P2093
P2860
P356
P1433
P1476
Liver NF-kappaB and AP-1 DNA binding in obese patients.
@en
P2093
A Verónica Araya
Attila Csendes
Catherine Santibañez
Daniela Haim
Fernando Maluenda
Gladys Smok
Gladys Tapia
Guillermo Rencoret
Jaime Castillo
Jaime Poniachik
P2860
P304
P356
10.1038/OBY.2008.601
P577
2009-01-22T00:00:00Z